

FOR IMMEDIATE RELEASE

Contact: Mattson Communications, Inc.
Kathy Mattson 312-988-9352
kathy@mattsonpr.com

TransMolecular Appoints E. Michael Egan As Chief Executive Officer

Seasoned Drug Commercialization Executive Brings 25 Years of Academic and Industrial Biotechnology Experience

BIRMINGHAM, AL – June 9, 2005 – TransMolecular, Inc., a biotechnology company focused on cancer drug research, today announced the appointment of E. Michael Egan as chief executive officer.

Mr. Egan served most recently as senior vice president of commercial development for GenVec, Inc. (Nasdaq:GNVC), a clinical-stage biopharmaceutical company developing gene-based medicines to treat cancer, heart disease and ophthalmic disorders. Prior to its merger with GenVec in 2003, Mr. Egan served as senior vice president, corporate development and chief operating officer of Diacrin, Inc., a biotechnology company that is developing cell transplantation technology for treating human diseases characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. Over a ten-year period, Mr. Egan moved nine product candidates from research to clinical development; the initial product was the first clinical evaluation of xenotransplantation approved by the FDA. He also established an independent joint venture with Genzyme Corporation for the development of xenotransplantation products for Parkinson's and Huntington's diseases. Mr. Egan was a key member of the management team involved in Diacrin's initial and follow-on public offerings, raising more than \$60 million for the company.

"I am excited to be joining the TransMolecular team at such a pivotal time," stated Mr. Egan. "Clinical results thus far are strong, and I am pleased to have the opportunity to lead a talented team that has the potential to revolutionize how we approach severely debilitating and previously untreatable diseases such as glioma."

Previously, Mr. Egan held a series of positions of increasing responsibility in the areas of corporate development, product sales and scientific research at Repligen Corporation, a biopharmaceutical company focused on the development of drugs for diseases that affect the central nervous system. Partnerships established during his ten-year tenure include those with Eli Lilly, Merck, Centocor and Sandoz. Mr. Egan began his career as a researcher at the Dana-Farber Cancer Institute, Division of Medicine. Mr. Egan is a graduate of Boston College with a B.S. in biology, and earned a Certificate of Special Studies in Administration and Management from Harvard University.

"The addition of Michael Egan to TransMolecular's team is a tremendous asset," said Lyle A. Hohnke, Ph.D., chairman of TransMolecular's board of directors and a partner at Tullis-Dickerson & Co., Inc., an investor in the company. "The company's clinical progress over the past few years has been tremendous. His experience and insight will help continue this momentum as we move into the next stages of its development." Mr. Egan replaces Matthew A. Gonda, Ph.D., who left the company at the end of April to pursue other opportunities.

In commenting upon Dr. Gonda's contributions to the company, Dr. Hohnke said, "Matt did a great job in translating research results into novel product opportunities and in working with

many clinical investigators and the FDA to move TransMolecular's lead product from concept into a phase II clinical trial. He has tremendous passion and the company's future is bright as a result of his leadership over the past six years." Dr. Gonda led TransMolecular through two rounds of venture funding during his tenure, raising greater than \$42 million in challenging financing times.

TransMolecular announced earlier this month that it had initiated a phase II clinical study of ¹³¹I-TM-601 in adult patients with recurrent high-grade glioma. ¹³¹I-TM-601 is a radiopharmaceutical containing a synthetic version of chlorotoxin, a substance derived from scorpion venom. Chlorotoxin, or TM-601, specifically seeks out and binds to a receptor expressed on tumor cells, but not on normal cells. It acts as the guidance system that delivers a radioactive payload to its target, killing the tumor cells and minimizing collateral damage to normal cells. ¹³¹I-TM-601 has received Orphan Drug and Fast Track Development Program status from the FDA and phase II studies are being conducted across the country.

ABOUT GLIOMA

Glioma is highly invasive, sending cancerous cells throughout the brain and spinal cord. Surgical techniques fail to eradicate the tumor and other adjuvant therapies are inadequate. Brain cancers are among the most difficult and expensive cancers to treat. About 36,000 primary brain tumors are reported in the U.S. each year; of these, more than 17,000 are diagnosed with high-grade gliomas. About half of these patients die within the first year, according to the American Cancer Society.

ABOUT TRANSMOLECULAR, INC.

TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat diseases having inadequate pharmaceutical alternatives, including cancer and pain. Research on TransMolecular's product pipeline based on a small peptide derived from scorpion venom that is expected to be useful in treating a wide variety of cancers is ongoing. More information can be found at www.transmolecular.com.